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Protein SUMOylation has been implicated in the pathogenesis of ischemic stroke. However, the
underlying mechanisms remain unclear. Here, we found that global brain ischemia evokes a sus-
tained elevation of GluK2 SUMOylation in the rat hippocampal CA1 region. Over-expression of
wild-type GluK2, but not SUMOylation-deﬁcient mutant, signiﬁcantly increased the activity of
MLK3 and JNK3 after kainate stimulation. SUMOylation deﬁciency attenuated the kainate-
stimulated interaction between MLK3 and GluK2. In addition, inhibition of kainate-evoked GluK2
endocytosis decreased the activation of MLK3–JNK3 signaling and the binding of MLK3–GluK2 in
cultured cortical neurons. These results suggest that the internalization of GluK2 following SUMO
modiﬁcation promotes its binding with MLK3, thereby activating the MLK3–JNK3 pathway, which
may be responsible for ischemic neuronal cell death.
Structured summary of protein interactions:
MLK3 physically interacts with GluK2 by anti bait coimmunoprecipitation (View Interaction: 1, 2)
SUMO1 physically interacts with GluK2 by anti bait coimmunoprecipitation (View interaction)
MLK3 physically interacts with GluK2 by anti bait coimmunoprecipitation (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Excitotoxicity is a major mechanism in ischemic brain damageSUMOylation, an important posttranslational protein modiﬁca-
tion, involves covalent attachment of a small ubiquitin-likemodiﬁer
(SUMO) to its substrate at a lysine residue in a reversible fashion
[1,2]. Three SUMO family members are known to exist in the brain
of vertebrate: SUMO1, SUMO2, and SUMO3. Accumulating evidence
has shown that protein SUMOylation is integral to diverse physio-
logical neuronal functions [3–5]. Furthermore, massively increased
SUMOylation by both SUMO1 and SUMO2/3 has been observed in
both global and focal cerebral ischemic animal models [6–8], sug-
gesting a critical role for SUMOylation in neuropathologic processes
following ischemic stroke. However, target proteins for activated
SUMOylation and their respective contributions to cell death
following brain ischemia remain to be elucidated.chemical Societies. Published by E
yl-4-isoxazolepropionic acid;
3, c-Jun N-terminal kinase 3;
ed lineage kinase 3; NMDA,
diﬁer.
of Brain Disease Bioinforma-
lar Biology, Xuzhou Medical
a. Fax: +86 516 8583 4231.[9,10]. After an ischemic episode, over-activation of glutamate
receptors triggers excessive intracellular signaling, eventually
leading to neuronal cell death, a process collectively known as
excitotoxicity. Glutamate receptors are classiﬁed as a-amino-3-hy-
droxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate, and
N-methy-D-aspartate (NMDA) receptors as well as metabotropic
glutamate receptors. Recently, glutamate receptor proteins includ-
ing kainate receptors and metabotropic glutamate receptors have
been identiﬁed as SUMO targets [11–13]. There are ﬁve types of
kainate receptor subunits: GluK1–5, formerly known as GluR5–7,
KA1, and KA2, respectively. It is reported that GluK2 is SUMOylated
by SUMO1 at the C-terminal K886 residue in response to kainate
stimulation. SUMOylation of GluK2 is required for agonist-induced
endocytosis of GluK2-containing kainate receptors and is involved
in the regulation of synaptic transmission [11]. In this study, we re-
port enhanced conjugation of GluK2 by SUMO1 following global
brain ischemia. To identify the contribution of such SUMOylation
to post-ischemic cell death and to elucidate the underlying molec-
ular mechanisms, we investigated the role of GluK2 SUMOylation
in the activation of mixed lineage kinase 3 (MLK3) and c-Jun N-ter-
minal kinase 3 (JNK3) following induction with kainate.lsevier B.V. All rights reserved.
Fig. 1. Global ischemia (5, 15, and 30 min) increases the level of GluK2
SUMOylation in the rat hippocampal CA1 region. (A) Immunoblot analysis of
GluK2 expression in ischemic (15 min) hippocampal CA1 samples with or without
NEM. (B) GluK2 SUMOylation after 15 min of brain ischemia. Samples from sham-
or ischemia-operated rats were immunoprecipitated with an anti-SUMO1 antibody
or non-speciﬁc mouse IgG (Mo.IgG), followed by blotting with an anti-GluK2
antibody. (C) GluK2 SUMOylation at different times (5, 15, and 30 min) of ischemia.
Samples were immunoprecipitated with an anti-SUMO1 antibody and then blotted
with an anti-GluK2 antibody. (D) Levels of SUMOylated GluK2 were normalized to
total GluK2. Relative levels were normalized to sham. Data are shown as mean ± SD
(n = 4). ⁄P < 0.05 vs. sham group.
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2.1. Antibodies
Rabbit monoclonal anti-GluK2/3 (clone NL9, #04-921) and
anti-JNK3 (clone C05T, #04-893) antibodies were purchased from
Millipore Biotechnology (Temecula, CA). A rabbit polyclonal anti-
p-MLK3 antibody (#2811) was obtained from Cell Signal Biotech-
nology (Beverly, MA). Mouse monoclonal anti-SUMO1 (D-11),
rabbit polyclonal anti-MLK3 (sc-13072), mouse monoclonal anti-
p-JNKs (G-7), and rabbit polyclonal anti-actin (sc-10731) antibod-
ies were purchased from Santa Cruz Biotechnology (Santa cruz,
CA). Alkaline phosphatase (AP)-conjugated goat anti-rabbit IgG
was obtained from Sigma (Saint Louis, MO).
2.2. Brain ischemia and sample preparation
All experiments were performed in accordance with the guide-
lines of the local Animal Care Committee. Adult male Sprague–
Dawley rats weighing 250–300 g were given free access to food
and water before surgery. Global brain ischemia was induced by
the four-vessel occlusion method (4-VO) as previously described
[14]. Brieﬂy, vertebral arteries were electrocauterized under anes-
thesia with chloral hydrate (300–350 mg/kg, i.p.). Ischemia was
induced by occluding carotid arteries with aneurysm clips on the
following day. The sham operation was performed using the same
surgical procedures except for occlusion of carotid arteries.
For brain tissue preparation, the hippocampal CA1 regions were
isolated after the indicated times of ischemia and rapidly frozen in
liquid nitrogen. Samples were homogenized in ice-old homogeni-
zation buffer [14]. For detection of SUMO-conjugated GluK2,
N-ethylmaleimide (NEM, 20 mmol/L) was added to the buffer to
inhibit de-SUMOylation in vitro. The supernatants were collected
and protein concentrations were determined by the Lowry meth-
od. Samples were stored at 80 C until use.
2.3. SH-SY5Y cell culture and plasmid transfection
Human neuroblastoma SH-SY5Y cells were maintained in Dul-
becco’s modiﬁed Eagle’s medium (DMEM; Gibco/Invitrogen)
(Grand island, NY) supplemented with 10% fetal bovine serum
(FBS; Gibco-BRL, Germany). A SUMOylation-deﬁcient mutant
GluK2 K886R was generated using the QuikChange II XL site-direc-
ted mutagenesis kit from Stratagene (La Jolla, CA). Recombinant
plasmids coding for wild-type of GluK2 (GluK2 WT) or GluK2
K886R based on the pcDNA3.1 vector (Invitrogen) were transfected
into cells with Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol. After 24 h of transfection, the cells were
stimulated with kainate (100 lmol/L) for the indicated times and
then harvested in ice-cold homogenization buffer.
2.4. COS-7 cell culture and plasmid transfection
COS-7 cells were maintained in DMEM supplemented with 10%
FBS. Recombinant plasmids coding wild-type GluK2 and MLK3
based on the pcDNA3.1 vector were introduced into cells with
polyetherimide (PEI; Invitrogen). After 24 h of transfection, the
cells were harvested in ice-cold homogenization buffer.
2.5. Cortical neuron culture
Primary cortical neurons from 18-d-old embryonic Sprague–
Dawley rats were plated onto poly-D-lysine coated culture dishes
at 0.8  105 cells/cm2 as previously described [15]. Neurons plated
for 14 d in vitro were used for all experiments and then harvested
in ice-cold homogenization buffer.2.6. Surface biotinylation
After kainate stimulation, live cortical neurons were surface
biotinylated on ice using Ez link sulfo-NHS-SS-Biotin (Pierce)
(Rockford, IL). Cell lysates (200 lg) were incubated with 75 mL of
immobilized NeutrAvidin (Pierce) for precipitation of biotinylated
proteins. Surface proteins and total cell lysates were subjected to
immunoblot analysis using a rabbit monoclonal antibody against
GluK2/3.
2.7. Immunoprecipitation
Sample proteins were incubated overnight at 4 C with appro-
priate antibodies diluted in immunoprecipitation buffer [16]. For
detection of SUMOylated GluK2, NEM (20 mmol/L) was added to
the immunoprecipitation buffer. After the addition of protein
A/G, the mixture was incubated at 4 C for an additional 2 h.
Samples were washed three times with immunoprecipitation buf-
fer and eluted by boiling for 5 min in 4  Laemmli sample buffer.
Fig. 2. GluK2 SUMOylation enhances kainate-induced MLK3 and JNK3 activation in SH-SY5Y cells. After transfection with GluK2 WT and GluK2 K886R, SH-SY5Y cells were
stimulated with kainate (100 lmol/L) for different times (3, 10, and 30 min). (A) MLK3 activation was determined using an anti-p-MLK3 antibody. Activation of JNK3 was
measured by immunoprecipitation with an anti-p-JNK antibody and immunobloting with an anti-JNK3 antibody. GluK2, MLK3, and JNK3 expression were detected by
corresponding antibodies. (B) Activation levels of MLK3 (B1) and JNK3 (B2) were normalized to total MLK3 and JNK3, respectively. Relative levels were normalized to WT/
0 min. Data are expressed as mean ± SD (n = 3). ⁄P < 0.05 vs. 0 min. #P < 0.05 WT vs. K886R.
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Sample proteins solubilized in Laemmli sample buffer were sep-
arated by SDS–PAGE and then electrotransferred onto a nitrocellu-
lose membrane (pore size: 0.45 lm). After blocking in 1% bovine
serum albumin (BSA), the membrane was incubated overnight
with the indicated primary antibody. Detection was carried out
by appropriate AP-conjugated IgG and developed with NBT/BCIP
assay kit (Promega).
2.9. Statistical analysis
For each type of experiment, data were obtained from at least
three independent measurements. The results are expressed as
mean ± standard deviation (SD). A student’s t-test was used for sta-
tistical comparison of differences, with P < 0.05 considered
signiﬁcant.3. Results
3.1. Transient global ischemia increases GluK2 SUMOylation in the rat
hippocampal CA1 subﬁeld
We ﬁrst detected a change in the pattern of SUMOylated GluK2
following global brain ischemia in the hippocampal CA1 subregion,
which is one of the most vulnerable areas to global ischemia.
SUMOylation is a reversible pathway. NEM, an irreversible inhibi-
tor of cysteine peptidases, was added to the homogenization buffer
to inhibit de-SUMOylation of GluK2. Immunoblot analysis of ische-
mic (15 min) samples revealed two bands corresponding to GluK2
in the presence of NEM, the upper band was shift by about 10 kDa
and was consistent with SUMO1 conjugation (Fig. 1A). As demon-
strated by immunoprecipitation with a mouse anti-SUMO1 anti-
body followed by immunoblotting with an anti-GluK2 antibody,
the amount of SUMOylated GluK2 was greater in the ischemia
1262 Q.-J. Zhu et al. / FEBS Letters 586 (2012) 1259–1264group compared to that of the sham-operated group. In contrast,
immunoprecipitation with a non-speciﬁc mouse IgG showed no
corresponding bands (Fig. 1B). The levels of SUMOylated GluK2
at the end of various time points following commencement of
brain ischemia (5, 15, and 30 min) were determined in anti-SUMO1
immunoprecipitates. The results showed that the level of SUMOy-
lated GluK2 increased signiﬁcantly after 15 min and increased up
to 3 folds after 30 min of brain ischemia (Fig. 1C and D). In contrast,
a short time (5 min) of brain ischemia did not cause any changes to
the level of SUMOylated GluK2. These results suggest a potential
role of GluK2 SUMOylation in ischemic neuronal cell death.
3.2. GluK2 SUMOylation increases the phosphorylation (activation) of
MLK3 and JNK3, as well as the binding of MLK3–GluK2 following
stimulation with kainate
The activation of MLK3 and downstream JNK3 signal cascades
mediated by GluK2-containing kainate receptors has been shownFig. 3. SUMOylation-deﬁciency of GluK2 diminishes kainate-induced binding of
MLK3–GluK2. (A) MLK3 and GluK2 bind to each other in COS-7 cells measured by
immunoprecipitation with an anti-MLK3 antibody followed by immunoblotting
with an anti-GluK2 antibody. (B) After GluK2 WT and GluK2 K886R transfection,
SH-SY5Y cells were stimulated by kainate (100 lmol/L). Binding of MLK3 and GluK2
was measured by immunoprecipitation with an anti-MLK3 antibody followed by
immunoblotting with an anti-GluK2 antibody. The expression levels of MLK3 and
GluK2 were determined using anti-MLK3 and anti-GluK2 antibodies. (C) Relative
levels of MLK3–GluK2 interaction were normalized to WT/0 min. Data are
expressed as mean ± SD (n = 3). ⁄P < 0.05 vs. 0 min. #P < 0.05 WT vs. K886R.to be involved in post-ischemic neuronal cell death [14,16,17]. To
deﬁne the roles of GluK2 SUMOylation in MLK3–JNK3 signaling
events, SH-SY5Y cells transfected with plasmids coding for full
length GluK2 WT or a SUMOylation-deﬁcient mutant GluK2
K886R were treated with kainate (100 lmol/L) for different times
(3, 10, and 30 min). As shown in Fig. 2, kainate treatment resulted
in increased phosphorylation of MLK3 and JNK3 in GluK2 WT-
expressing SH-SY5Y cells; however, the activation of either MLK3
or JNK3 showed no change in cells expressing the GluK2 K886R
mutant, especially after kainate stimuli for 10 and 30 min. The
total protein levels of MLK3 and JNK3 were not altered.
To clarify the mechanisms underlying the role of GluK2 SUMOy-
lation in MLK3–JNK3 signal transduction, the interaction between
GluK2 and MLK3 was examined. The binding of GluK2 to MLK3
was shown in COS-7 cells co-transfected with GluK2 and MLK3
plasmids by co-immunoprecipitation (Fig. 3A). Kainate stimuli pro-
moted the interaction of GluK2 with MLK3, but SUMOylation-deﬁ-
ciency of GluK2 decreased this binding in SH-SY5Y cells (Fig. 3B
and C).
The above analyses indicate that GluK2 SUMOylation is consis-
tent with GluK2–MLK3 interaction and positively regulates the
activation of the MLK3–JNK3 pathway.
3.3. Inhibition of kainate-evoked internalization attenuates the
activation of MLK3–JNK3 and MLK3–GluK2 binding
Although it has been reported that the endocytosis of GluK2 oc-
curs rapidly after SUMOylation [11], the relationship between
GluK2 endocytosis and kainate excitotoxicity remains unclear.
We therefore aimed to address the signiﬁcance of GluK2-contain-
ing kainate receptor endocytosis to downstream MLK3–JNK3 sig-
naling. Monodansylcadavenrine (MDC) has been shown to inhibit
endocytosis [18]. Here, pre-treatment of MDC blocked GluK2 endo-
cytosis stimulated by kainate (Fig. 4A). Kainate stimuli increased
the activation of MLK3 and JNK3 in primary cortical neurons at
10 and 30 min. Pre-incubation with MDC (100 lmol/L), which pre-
vents endocytosis of GluK2, diminished the kainate-stimulated
activation of MLK3 and JNK3 (Fig. 4B and C). Also, the kainate-stim-
ulated binding of MLK3–GluK2 was weaker in MDC pre-treated
primary cortical neurons than in neurons without MDC (Fig. 5).
This data suggest that the internalization of GluK2-containing kai-
nate receptors after SUMO conjugation is in favor of more effective
binding to MLK3 and further facilitates MLK3 activation.4. Discussion
Excitotoxicity mediated by excessive activation of glutamate
receptors leads to neurodegenerative disorders resulting from
brain ischemia. However, the clinical application of glutamate
receptor antagonists is limited by severe side effects. Postsynaptic
signaling cascades by over-activation of glutamate receptors may
present a potential target for ischemic stroke therapy. In recent
years, protein SUMOylation has been shown to be an important
regulator of diverse signaling processes. Here, we provide the ﬁrst
evidence that SUMO1 modiﬁcation of glutamatergic kainate recep-
tor subunit GluK2 is associated with cellular MLK3–JNK3 signaling
cascades.
Kainate receptors distribute ubiquitously in the brain. Knock-
down of GluK2 by antisense oligodeoxynucleotides protects
against ischemic neuronal loss in the rat hippocampal CA1 region
[14]. In addition, GluK2-deﬁcient mice exhibit resistance to neuro-
nal degeneration and seizures induced by kainate acid [19]. These
studies indicate that signaling via GluK2-containing kainate recep-
tors is an important event in the induction of neuronal toxicity. It
has been demonstrated that GluK2 SUMOylation down-regulates
Fig. 4. Inhibited endocytosis attenuates the activation of MLK3 and JNK3 in primary cortical neurons. Cortical neurons were incubated with MDC (100 lmol/L) for 30 min
prior to stimulation with kainate (100 lmol/L) for the indicated times. (A) Immunoblot of biotinylated surface and total GluK2. Relative levels (surface/total of GluK2) were
normalized to MDC/0 min. (B) MLK3 activation was determined using an anti-p-MLK3 antibody. Activation of JNK3 was measured by immunoprecipitation with an
anti-p-JNK antibody and immunobloting with an anti-JNK3 antibody. MLK3 and JNK3 expression levels were detected by anti-MLK3 and anti-JNK3 antibodies. (C) Activation
levels of MLK3 (C1) and JNK3 (C2) were normalized to total MLK3 and JNK3, respectively. Relative levels were normalized to MDC/0 min. Data are expressed as mean ± SD
(n = 3). ⁄P < 0.05 vs. 0 min. #P < 0.05 MDC vs. +MDC.
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induces rundown of kainate evoked excitatory postsynaptic
currents [11]. However, why brain ischemia still leads to neuronal
loss along with massive SUMOylated GluK2 remained unclear. Our
results revealed that SUMOylation-mediated endocytosis of
GluK2-containing kainate receptors activates neurotoxic MLK3 sig-
naling. Furthermore, MLK3 functions as an upstream initiator of
JNK3 signaling cascades, which is critical for excitotoxicity and
brain ischemia-induced neuronal apoptosis [20]. After brain ische-
mia, activated MLK3 kinases bind and activate MAPK kinase 4 and
MAPK kinase 7, which in turn phosphorylate and activate JNK3,
inducing cell apoptosis [16,17]. The facilitation effect of GluK2
SUMOylation on the MLK3–JNK3 pathway further highlights the
involvement of such SUMOylation in ischemic neurotoxicity.
Endocytosis, along with recycling, degradation, or lateral diffu-
sion, is responsible for changes in the surface expression and
compartmentalization of membrane receptors. Kainate stimulationinduces endocytic sorting of GluK2 to degradation, while NMDA
receptors mediate recycling of internalized GluK2 [21]. We specu-
lated that sustained activation of kainate receptors following brain
ischemia or high-dose kainate treatment may activate NMDA
receptors, leading to the recycling of GluK2-containing receptors.
This positive feedback loop facilitates MLK3–JNK3 activation and
subsequently results in neuronal damage.
Recently, studies suggested that protein SUMOylation is in-
volved in ischemic tolerance [22,23] and may have a neuroprotec-
tive role in cultured neurons and transgenic mice brains [24,25].
However, the reasons why ischemic damage still occurs even
though many proteins remain SUMOylated remain unknown. More
than 1000 proteins have been identiﬁed as potential SUMO
substrates, including nuclear, cytosolic, and plasma membrane
proteins. We believe that SUMOylation of various proteins may
play complex and varied functions in pathophysiological processes.
Further studies are required to explore these events.
Fig. 5. Inhibited endocytosis attenuates the interaction of MLK3 and GluK2 in
primary cortical neurons. Cortical neurons were incubated with MDC (100 lmol/L)
for 30 min prior to the stimulation of kainate (100 lmol/L) for the indicated times.
(A) Binding of MLK3 and GluK2 was measured by immunoprecipitation with an
anti-MLK3 antibody followed by immunoblotted with an anti-GluK2 antibody. The
expression levels of MLK3 and GluK2 were determined using anti-MLK3 antibody
and anti-GluK2 antibodies. (B) Relative levels of MLK3–GluK2 interaction were
normalized to MDC/0 min. Data are expressed as mean ± SD (n = 3). ⁄P < 0.05 vs.
0 min. #P < 0.05 MDC vs. +MDC.
1264 Q.-J. Zhu et al. / FEBS Letters 586 (2012) 1259–1264In conclusion, brain ischemia stimulates SUMO modiﬁcation of
GluK2 and leads to endocytosis of GluK2-containing kainate recep-
tors. Such internalization spatially facilitates the binding of GluK2
with MLK3 and subsequently activates MLK3 as well as the JNK3
downstream pathway. The interaction of MLK3 and GluK2 suggest
the MLK3–GluK2 complex as a potential therapeutic target for the
treatment of ischemic stroke.
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